{"id":"https://openalex.org/W3137318924","doi":"https://doi.org/10.7326/l20-1455","title":"Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment","display_name":"Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment","alternate_titles":[],"publication_year":2021,"publication_date":"2021-03-01","ids":{"openalex":"https://openalex.org/W3137318924","doi":"https://doi.org/10.7326/l20-1455","mag":"3137318924","pmid":"https://pubmed.ncbi.nlm.nih.gov/33721528"},"language":"en","primary_location":{"id":"doi:10.7326/l20-1455","doi":"https://doi.org/10.7326/l20-1455","is_oa":false,"landing_page_url":"https://doi.org/10.7326/l20-1455","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3137318924"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069149988","display_name":"Rao N. V. S. Mamidi","orcid":"https://orcid.org/0000-0003-1181-5283","observed_orcids":["https://orcid.org/0000-0003-1181-5283"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rao N.V.S. Mamidi","raw_affiliation_strings":["Janssen Research & Development, Raritan, New Jersey"],"raw_orcid":"https://orcid.org/0000-0003-1181-5283","affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, New Jersey","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047898874","display_name":"Damayanthi Devineni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Damayanthi Devineni","raw_affiliation_strings":["Janssen Research & Development, Raritan, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, New Jersey","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114009636","display_name":"Don Sun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Don Sun","raw_affiliation_strings":["Janssen Research & Development, Raritan, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, New Jersey","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044077375","display_name":"Yshai Yavin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yshai Yavin","raw_affiliation_strings":["Janssen Research & Development, Raritan, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, New Jersey","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074233460","display_name":"Norman R Rosenthal","orcid":"https://orcid.org/0000-0002-1649-4979","observed_orcids":["https://orcid.org/0000-0002-1649-4979"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Norman Rosenthal","raw_affiliation_strings":["Janssen Research & Development, Raritan, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research & Development, Raritan, New Jersey","institution_ids":["https://openalex.org/I4405282460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405282460"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"174","issue":"3","first_page":"431","last_page":"432"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.24770000576972961,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.24770000576972961,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.22920000553131104,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.1932000070810318,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":0.9150000214576721},{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":0.9940000176429749},{"id":"https://openalex.org/keywords/myotoxicity","display_name":"myotoxicity","score":0.8190000057220459},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.8270000219345093},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.8679999709129333},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9480000138282776},{"id":"https://openalex.org/keywords/rhabdomyolysis","display_name":"rhabdomyolysis","score":0.9399999976158142},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.7590000033378601},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.9100000262260437},{"id":"https://openalex.org/keywords/credence-trial","display_name":"CREDENCE trial","score":0.7120000123977661},{"id":"https://openalex.org/keywords/canvas-trial","display_name":"CANVAS trial","score":0.9459999799728394},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.4169999957084656},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6100000143051147},{"id":"https://openalex.org/keywords/pharmacogenetics","display_name":"pharmacogenetics","score":0.7990000247955322}],"concepts":[{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.9581520557403564},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9033925533294678},{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.7842483520507812},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.37154605984687805},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.36822932958602905},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.2986695468425751},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.27600109577178955},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.26761412620544434}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068896","descriptor_name":"Canagliflozin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000081030","descriptor_name":"Myotoxicity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.7326/l20-1455","doi":"https://doi.org/10.7326/l20-1455","is_oa":false,"landing_page_url":"https://doi.org/10.7326/l20-1455","pdf_url":null,"source":{"id":"https://openalex.org/S119722071","display_name":"Annals of Internal Medicine","issn_l":"0003-4819","issn":["0003-4819","1539-3704"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316812","host_organization_name":"American College of Physicians","host_organization_lineage":["https://openalex.org/P4310316812"],"host_organization_lineage_names":["American College of Physicians"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Internal Medicine","raw_type":"journal-article"},{"id":"pmid:33721528","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33721528","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of internal medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1999164183","https://openalex.org/W2131983256","https://openalex.org/W2234611863","https://openalex.org/W2554109120","https://openalex.org/W3047451499"],"related_works":["https://openalex.org/W3047451499","https://openalex.org/W3164052520","https://openalex.org/W4400140531","https://openalex.org/W7136034006","https://openalex.org/W3152341695","https://openalex.org/W2912146044","https://openalex.org/W2626446274","https://openalex.org/W1856577368","https://openalex.org/W2897803195","https://openalex.org/W2733460428"],"abstract_inverted_index":{"LettersMarch":[0],"2021Rosuvastatin":[1],"Myotoxicity":[2,399,418,434],"After":[3,400,419,435],"Starting":[4,401,420,436],"Canagliflozin":[5,402,421,437],"TreatmentRao":[6],"N.V.S.":[7,22],"Mamidi,":[8,23],"PhD,":[9,12],"Damayanthi":[10,37],"Devineni,":[11,38],"Don":[13,52],"Sun,":[14,53],"MD,":[15],"Yshai":[16,67],"Yavin,":[17,68],"MBChB,":[18],"Norman":[19,82],"Rosenthal,":[20,83],"MDRao":[21],"PhDJanssen":[24,39],"Research":[25,40,55,70,85,383],"&":[26,41,56,71,86,384,465],"Development,":[27,42,57,72,87,385],"Raritan,":[28,43,58,73,88,386],"New":[29,44,59,74,89,387],"JerseySearch":[30,45,60,75,90],"for":[31,46,61,76,91],"more":[32,47,62,77,92,152,355],"papers":[33,48,63,78,93],"by":[34,49,64,79,94,325,469],"this":[35,50,65,80,95],"author,":[36,51,66,81],"MDJanssen":[54,84],"MBChBJanssen":[69],"authorAuthor,":[96],"Article,":[97,378],"and":[98,113,124,172,180,245,249,277,357,379,414,430,445],"Disclosure":[99,380],"Informationhttps://doi.org/10.7326/L20-1455":[100],"SectionsAboutFull":[101],"TextPDF":[102],"ToolsAdd":[103],"to":[104,175,328],"favoritesDownload":[105],"CitationsTrack":[106],"CitationsPermissions":[107],"ShareFacebookTwitterLinkedInRedditEmail":[108],"TO":[109],"THE":[110],"EDITOR:":[111],"Brailovski":[112,212,408,424],"colleagues":[114],"(1)":[115],"report":[116,226],"the":[117,134,162,181,254,309],"first":[118],"drug\u2013drug":[119],"interaction":[120,284,322],"(DDI)":[121],"between":[122],"canagliflozin":[123,222],"a":[125,224,318,329,354],"statin.":[126],"However,":[127],"no":[128],"myotoxicity":[129,219],"signal":[130],"was":[131],"seen":[132],"in":[133,166,188,247,253,317,332],"clinical":[135,363],"development":[136],"program":[137,160],"(which":[138,150],"consisted":[139],"of":[140,157,282,286,308,472],">19":[141],"000":[142],"participants":[143],"receiving":[144],"canagliflozin)":[145],"or":[146],"during":[147],"postmarketing":[148],"use":[149,204],"totaled":[151],"than":[153,365],"4.9":[154],"million":[155],"patient-years":[156],"exposure).":[158],"This":[159],"included":[161],"long-term":[163],"CREDENCE":[164],"study":[165],"patients":[167,189],"with":[168,190,199,323],"type":[169,191],"2":[170,174,192],"diabetes":[171,193],"stage":[173],"3":[176],"chronic":[177],"kidney":[178],"disease":[179],"CANVAS":[182],"(CANagliflozin":[183],"cardioVascular":[184],"Assessment":[185],"Study)":[186],"Program":[187],"at":[194,393],"high":[195],"cardiovascular":[196],"risk,":[197],"both":[198],"approximately":[200],"70%":[201],"concomitant":[202],"statin":[203,333],"(":[205],">9%":[206],"received":[207],"rosuvastatin;":[208],"data":[209],"on":[210],"...References1.":[211],"E,":[213],"Kim":[214,412,428],"RB,":[215],"Juurlink":[216,416,432],"D.":[217],"Rosuvastatin":[218,243,417,433],"after":[220],"starting":[221],"treatment:":[223],"case":[225],"[Letter].":[227],"Ann":[228],"Intern":[229],"Med.":[230],"2020;173:585-7.":[231],"doi:10.7326/L20-0549":[232],"LinkGoogle":[233],"Scholar2.":[234],"Birmingham":[235],"BK,":[236],"Bujac":[237],"SR,":[238],"Elsby":[239,298],"R,":[240,299,349],"et":[241,273,304,350],"al.":[242,274,305,351],"pharmacokinetics":[244],"pharmacogenetics":[246],"Caucasian":[248],"Asian":[250],"subjects":[251],"residing":[252],"United":[255],"States.":[256],"Eur":[257],"J":[258,289,368],"Clin":[259,290,369],"Pharmacol.":[260,291,370],"2015;71:329-40.":[261],"[PMID:":[262,293,339,372],"25630984]":[263],"doi:10.1007/s00228-014-1800-0":[264],"CrossrefMedlineGoogle":[265,296,342,375],"Scholar3.":[266],"Mamidi":[267],"RNVS,":[268],"Dallas":[269],"S,":[270],"Sensenhauser":[271],"C,":[272],"In":[275],"vitro":[276],"physiologically-based":[278],"pharmacokinetic":[279],"based":[280],"assessment":[281],"drug-drug":[283,321],"potential":[285],"canagliflozin.":[287],"Br":[288,367],"2017;83:1082-96.":[292],"27862160]":[294],"doi:10.1111/bcp.13186":[295],"Scholar4.":[297],"Martin":[300],"P,":[301],"Surry":[302],"D,":[303],"Solitary":[306],"inhibition":[307],"breast":[310],"cancer":[311],"resistance":[312],"protein":[313],"efflux":[314],"transporter":[315],"results":[316],"clinically":[319],"significant":[320],"rosuvastatin":[324],"causing":[326],"up":[327],"2-fold":[330],"increase":[331],"exposure.":[334],"Drug":[335],"Metab":[336],"Dispos.":[337],"2016;44:398-408.":[338],"26700956]":[340],"doi:10.1124/dmd.115.066795":[341],"Scholar5.":[343],"Prueksaritanont":[344],"T,":[345],"Chu":[346],"X,":[347],"Evers":[348],"Pitavastatin":[352],"is":[353],"sensitive":[356],"selective":[358],"organic":[359],"anion-transporting":[360],"polypeptide":[361],"1B":[362],"probe":[364],"rosuvastatin.":[366],"2014;78:587-98.":[371],"24617605]":[373],"doi:10.1111/bcp.12377":[374],"Scholar":[376],"Author,":[377],"InformationAffiliations:":[381],"Janssen":[382],"JerseyDisclosures:":[388],"Disclosures":[389],"can":[390],"be":[391],"viewed":[392],"www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L20-1455.":[394],"PreviousarticleNextarticle":[395],"Advertisement":[396],"FiguresReferencesRelatedDetailsSee":[397],"AlsoRosuvastatin":[398],"Treatment:":[403],"A":[404],"Case":[405],"Report":[406],"Eugene":[407,423],",":[409,413,425,429,441,444],"Richard":[410,426],"B.":[411,427],"David":[415,431],"Treatment":[422,438],"Ahmad":[439],"Alamer":[440],"Charisse":[442],"Te":[443],"Maryam":[446],"T.":[447],"Fazel":[448],"Metrics":[449],"March":[450,458,462],"2021Volume":[451],"174,":[452],"Issue":[453,460],"3Page:":[454],"431-432":[455],"ePublished:":[456],"16":[457],"2021":[459,463,468],"Published:":[461],"Copyright":[464],"PermissionsCopyright":[466],"\u00a9":[467],"American":[470],"College":[471],"Physicians.":[473],"All":[474],"Rights":[475],"Reserved.PDF":[476],"downloadLoading":[477],"...":[478]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3137318924","counts_by_year":[],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2021-03-29T00:00:00"}
